Breakthrough candidemia in children: clinical and microbiological characteristics, therapeutic strategies and impact on outcomes (Q38741813)

6 September 2017

title

Breakthrough candidemia in children: clinical and microbiological characteristics, therapeutic strategies and impact on outcomes (English)

1 reference

6 September 2017

1 reference

Mei-Yin Lai

1

1 reference

6 September 2017

Jen-Fu Hsu

2

1 reference

6 September 2017

Shih-Ming Chu

3

1 reference

6 September 2017

I-Hsyuan Wu

4

1 reference

6 September 2017

Hsuan-Rong Huang

5

1 reference

6 September 2017

Chun-Chih Lin

6

1 reference

6 September 2017

I-Ta Lee

7

1 reference

6 September 2017

Ming-Chou Chiang

8

1 reference

6 September 2017

Ren-Huei Fu

9

1 reference

6 September 2017

Ming-Horng Tsai

10

1 reference

6 September 2017

publication date

13 March 2017

1 reference

6 September 2017

number of pages

11

1 reference

based on heuristic

inferred from page(s)

published in

Future Microbiology

1 reference

6 September 2017

volume

12

1 reference

6 September 2017

page(s)

695-705

1 reference

Epidemiology and outcome of candidaemia in patients with oncological and haematological malignancies: results from a population-based surveillance in Spain

6 September 2017

cites work

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0223

Invasive Candida infections in surgical patients in intensive care units: a prospective, multicentre survey initiated by the European Confederation of Medical Mycology (ECMM) (2006-2008).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0223

Pathogen-Specific Clustering of Nosocomial Blood Stream Infections in Very Preterm Infants.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0223

Clinical and molecular characteristics of bloodstream infections caused by Candida albicans in children from 2003 to 2011.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0223

Uncommon Candida Species Fungemia among Cancer Patients, Houston, Texas, USA.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0223

Risk factors for late recurrent candidaemia. A retrospective matched case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0223

Impact of therapeutic strategies on the prognosis of candidemia in the ICU.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0223

Impact on hospital mortality of catheter removal and adequate antifungal therapy in Candida spp. bloodstream infections

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0223

Initial use of echinocandins does not negatively influence outcome in Candida parapsilosis bloodstream infection: a propensity score analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0223

Septic shock attributed to Candida infection: importance of empiric therapy and source control

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0223

Breakthrough candidaemia in the era of broad-spectrum antifungal therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0223

In vitro susceptibility of breakthrough Candida bloodstream isolates correlates with daily and cumulative doses of fluconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0223

Breakthrough candidaemia caused by phenotypically susceptible Candida spp. in patients with haematological malignancies does not correlate with established interpretive breakpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0223

Breakthrough candidemia due to multidrug-resistant Candida glabrata during prophylaxis with a low dose of micafungin.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0223

Not just little adults: candidemia epidemiology, molecular characterization, and antifungal susceptibility in neonatal and pediatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0223

A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0223

Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0223

Early initiation of appropriate treatment is associated with increased survival in cancer patients with Candida glabrata fungaemia: a potential benefit from infectious disease consultation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0223

Breakthrough invasive fungal disease in patients receiving posaconazole primary prophylaxis: a 4-year study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0223

Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0223

Candida species distribution and antifungal susceptibility testing according to European Committee on Antimicrobial Susceptibility Testing and new vs. old Clinical and Laboratory Standards Institute clinical breakpoints: a 6-year prospective candida

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0223

EUCAST technical note on isavuconazole breakpoints for Aspergillus, itraconazole breakpoints for Candida and updates for the antifungal susceptibility testing method documents

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0223

Prior caspofungin exposure in patients with hematological malignancies is a risk factor for subsequent fungemia due to decreased susceptibility in Candida spp.: a case-control study in Paris, France

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0223

Clinical and Microbiological Characteristics of Breakthrough Candidemia in Allogeneic Hematopoietic Stem Cell Transplant Recipients in a Japanese Hospital.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0223

Prognostic factors and historical trends in the epidemiology of candidemia in critically ill patients: an analysis of five multicenter studies sequentially conducted over a 9-year period

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0223

Recurrent late-onset sepsis in the neonatal intensive care unit: incidence, clinical characteristics and risk factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0223

Predictors of clinical and microbiological treatment failure in neonatal bloodstream infections

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0223

Risk factors and outcomes for multidrug-resistant Gram-negative bacteremia in the NICU.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0223

Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0223

21 January 2018

Identifiers

DOI

10.2217/FMB-2016-0223

1 reference

6 September 2017

1 reference